Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 13

recruiting
3 968
countries
28
conditions
2 103

604 trials match your criteria

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANGIOTENSIN II

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab

Vulval cancer

Recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Endometrial cancer+13

Recruiting

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan

Acute leukaemia

Recruiting

Study on the Safety and Tolerability of SNDX-5613 for Patients with Relapsed or Refractory Acute Leukemias

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Revumenib

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.